Policy & Regulation
Ionis' TRYNGOLZA recommended for EU approval in severe hypertriglyceridemia
16 October 2026 - Biotechnology company Ionis Pharmaceuticals Inc (Nasdaq:IONS) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...
FDA approves Genentech's Enspryng as first at-home subcutaneous treatment for thyroid eye disease
16 October 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Friday that it has received US Food and Drug Administration (FDA) approval fo...
Expression Therapeutics awarded USD2m grant to advance potential new therapy for children with high-risk neuroblastoma
16 October 2026 - Expression Therapeutics Inc, a clinical-stage gene and cell therapy company, announced on Thursday that it has been awarded a National Cancer Institute (NCI) Small Business Innovatio...
EMA issues positive CHMP opinion for Revolution Medicines' RASONQUE in metastatic pancreatic cancer
15 October 2026 - US-based oncology company Revolution Medicines, Inc. (NASDAQ: RVMD) on Thursday said it has received a positive opinion from the European Medicines Agency's Committee for Medici...
Edesa Biotech receives FDA clearance to expand EB06 vitiligo study into the US
15 October 2026 - Canadian clinical-stage biopharmaceutical company Edesa Biotech, Inc. (NASDAQ: EDSA) said on Thursday it has received US FDA clearance for its Investigational New Drug application fo...
LTR Pharma launches Roxus nasal spray for ED in the US
15 October 2026 - Australian pharmaceutical company LTR Pharma Limited (ASX: LTP) on Thursday introduced Roxus, a prescription nasal spray for erectile dysfunction (ED), to patients across the United ...